Together, these data confirmed that ERO1α-deficient PDA cells exhibit impaired tumor development in vitro, so we next performed xenograft experiments in Ncr-nude mice to determine whether these cells also displayed reduced oncogenic potential in vivo. This evidence concerns the gene ERO1A and Patent ductus arteriosus.